Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Surufatinib with Chemoradiotherapy in LS-SCLC
NCT06719700Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Nov 2028
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, surufatinib in small cell lung cancer (SCLC), sponsored by Sun Yat-sen University. Started Nov 2024; status: recruiting.
02
Drugs
toripalimabsurufatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06719700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719700.